FPR2 and heart failure: Phase I clinical trials reported promising tissue protective actions with other small-molecule ALX/FPR2 agonists, such as compound ACT-389949 (Actelion) (249), and compound BMS986235 (Bristol –Myers Squibb) (250) in heart failure.